Microbio awarded AMGC support for sovereign manufacture of core IP for biothreat tests

Australian biotech company Microbio has been awarded an Australian Government Advanced Manufacturing Growth Centre (AMGC) co-investment of $407,000 to enable the company to establish sovereign manufacturing capabilities in Australia for a test to identify potential biological threats.

The company will manufacture specific oligonucleotides, a unique component used in its product suite, which includes InfectID-BSI, InfectID-COVID and InfectID-SSBA: its patented one-tube, seven-pathogen test to rapidly detect Security Sensitive Biological Agents (SSBAs). 

Read more in the Media Release: 220203 Microbio awarded AMGC support for sovereign manufacture of biothreat tests